Published
Update
Video length: 2 min.
Article written by
In Chicago, in the United States, specialists from all over the world are meeting and confirming a leap forward in the fight against cancer, with targeted and personalized therapy. The tests are already in progress, in particular that carried out by the Curie institute.
It could be a revolution against the recurrence of certain cancers. A French vaccine is in the test phase on patients with head and neck cancer. The goal is to prevent relapses. The first results are conclusive: out of 16 patients treated, none relapsed. “This product, TG4050, has the particularity of being unique for each patient. We will manufacture a therapeutic vaccine that responds to the characteristics of each patient’s tumor, and even adapts to each patient’s immune system”explains Hedi Ben Brahim, President of Transgene.
A form of vaccine in full development
Prior to administration, a sample of each patient’s tumor is analyzed. Thanks to artificial intelligence, scientists determine the best 30 mutations in cancer cells, out of nearly 3,000, likely to give an immune response. This form of therapeutic vaccine is in full development. The second phase of testing on patients with head and neck cancer should begin within a few months. However, it will take several years before it can be put on the market.
View comments